Perspectives on reprograming cancer-associated dendritic cells for anti-tumor therapies.
Perspectives on reprograming cancer-associated dendritic cells for anti-tumor therapies.
复制标题
DOI：
10.3389/fonc.2014.00072
复制
发表时间：
2014
影响因子：
4.7
通讯作者：
Alnaeeli M
中科院分区：
文献类型：
--
作者：
Benencia F;Muccioli M;Alnaeeli M
近年来，肿瘤微环境（TME）在癌症进展中的相关性引起了广泛关注。研究表明，TME 能够使免疫系统中负责肿瘤清除的各种成分失活，从而有利于癌细胞生长和肿瘤转移。特别是，TME 对抗原呈递细胞（例如树突状细胞 (DC)）的影响包括使这些细胞无法促进特异性免疫反应或将其转化为能够诱导调节性 T 细胞的抑制性细胞。此外，在TME的影响下，DC可以产生诱导新生血管形成的生长因子，从而进一步促进肿瘤的发展。有趣的是，与癌症相关的树突状细胞含有肿瘤抗原，因此如果适当地重新激活，有可能成为原位抗肿瘤疫苗。这篇透视文章概述了原位重编程癌症相关树突状细胞以产生抗肿瘤免疫反应的科学背景和实验基础。
In recent years, the relevance of the tumor microenvironment (TME) in the progression of cancer has gained considerable attention. It has been shown that the TME is capable of inactivating various components of the immune system responsible for tumor clearance, thus favoring cancer cell growth and tumor metastasis. In particular, effects of the TME on antigen-presenting cells, such as dendritic cells (DCs) include rendering these cells unable to promote specific immune responses or transform them into suppressive cells capable of inducing regulatory T cells. In addition, under the influence of the TME, DCs can produce growth factors that induce neovascularization, therefore further contributing to tumor development. Interestingly, cancer-associated DCs harbor tumor antigens and thus have the potential to become anti-tumor vaccines in situ if properly reactivated. This perspective article provides an overview of the scientific background and experimental basis for reprograming cancer-associated DCs in situ to generate anti-tumor immune responses.